Bin Liu

Bin Liu, Ph.D., is a scientist and drug discovery leader with extensive experience in metabolic disease, rare disease, and translational pharmacology. He currently leads the development of in vitro metabolic pharmacology capabilities at WuXi AppTec, supporting drug discovery across obesity, diabetes, MASH, cardiovascular and kidney diseases. Previously, he served as a Principal Scientist at Novo Nordisk and as a Senior Scientist at the Danish Cancer Society. His expertise spans target discovery and validation, translational biology, oligonucleotide therapeutics, and advanced in vitro models, with experience taking programs from early discovery toward clinical development.